Detalhe da pesquisa
1.
Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives.
Ann Hematol
; 101(5): 963-978, 2022 May.
Artigo
Inglês
| MEDLINE | ID: mdl-35201417
2.
Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19).
Br J Haematol
; 149(3): 376-82, 2010 May.
Artigo
Inglês
| MEDLINE | ID: mdl-20230405
3.
Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study.
Eur J Haematol
; 90(6): 531-2, 2013 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-23506097
4.
Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial.
J Clin Oncol
; 34(9): 972-9, 2016 Mar 20.
Artigo
Inglês
| MEDLINE | ID: mdl-26811524
5.
High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
J Clin Oncol
; 32(3): 219-28, 2014 Jan 20.
Artigo
Inglês
| MEDLINE | ID: mdl-24297940
6.
Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17).
J Clin Oncol
; 31(35): 4424-30, 2013 Dec 10.
Artigo
Inglês
| MEDLINE | ID: mdl-24127442